Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
hyaluronate · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| sodium hyaluronate | DRUG | - |
The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to po...
Hyaluronate is used for osteoarthritis of the shoulder. It is being developed as a small molecule treatment for this musculoskeletal condition. The drug is currently in Phase 3 clinical development and is being studied in patients with painful shoulder osteoarthritis.
Hyaluronate is being developed by Sanofi, a biopharmaceutical company traded on the stock exchange under the ticker SNY. Sanofi is conducting clinical research on hyaluronate for the treatment of osteoarthritis of the shoulder.
Hyaluronate is in Phase 3 clinical development. It is an investigational drug for osteoarthritis of the shoulder and has not yet been approved by regulatory authorities. The Phase 3 trial for hyaluronate has been completed.
Hyaluronate has been studied in a Phase 3 clinical trial with the identifier NCT00377624, titled "HUPS: Hyalgan Use in Painful Shoulder." This completed trial enrolled 602 participants with osteoarthritis of the shoulder in the United States. The study included patients aged 35 years and older.
Yes, hyaluronate is the same as Hyalgan. The Phase 3 clinical trial NCT00377624 is titled "HUPS: Hyalgan Use in Painful Shoulder," indicating that Hyalgan is the name used for hyaluronate in this study. Both names refer to the same drug being developed for osteoarthritis of the shoulder.